Page header

Recommendation of the President – Cabometyx (cabozantinib)

On 2 June 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 76/2026 on the inclusion of the medicinal product Cabometyx (cabozantinib) in the reimbursement program for the treatment of pancreatic neuroendocrine tumors (pNET) and extrapancreatic neuroendocrine tumors (epNET)

Publication in Public Information Bulletin (BIP) >>